Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05573685 · ClinicalTrials.gov registry record · NA

Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMo™ Component Training

A NA study of Rheumatoid Arthritis and Fibromyalgia, sponsored by Click Therapeutics.

Completed
Registry status
NA
Development phase
124
Enrollment target
1
Study location

NCT05573685 is a NA study of Rheumatoid Arthritis and Fibromyalgia that has completed, run by Click Therapeutics. The registered enrollment target is 124 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05573685, a NA study of Rheumatoid Arthritis and Fibromyalgia, has completed, sponsored by Click Therapeutics.

COMPLETED
Registry status
NA
Development phase
124 participants
Enrollment target
1
Study location

Study Summary

CT-100 is a platform that provides interactive, software based therapeutic components that may be used as part of a multimodal treatment in supplementary or standalone prescription or nonprescription software-based digital therapeutics (PDT/DTx), being developed by Click Therapeutics, Inc. (Click).

Interventions

  • DEVICE DiNaMo Study App
  • DEVICE Placebo App

Study Locations (1)

New York

  • Click Therapeutics - New York

Trial Details

FieldValue
Enrollment Target 124 participants
Start Date 2022-10-10
Est. Completion 2023-02-06
Phase NA

Sponsor

Click Therapeutics

15 total trials

What the Registry Record Tells You About NCT05573685

The ClinicalTrials.gov registry entry for NCT05573685 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (97% lower). The listed sponsor is Click Therapeutics, which has 15 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which DiNaMo Study App is the first listed.

NCT05573685 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT05573685 about?

NCT05573685 is a clinical study titled "Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMo™ Component Training". CT-100 is a platform that provides interactive, software based therapeutic components that may be used as part of a multimodal treatment in supplementary or standalone prescription or nonprescription software-based digital therapeutics (PDT/DTx), being developed by Click Therapeutics, Inc. (Click).

What is the current status of trial NCT05573685?

This trial is currently completed. It is a NA study. The enrollment target is 124 participants. The study started on 2022-10-10. Estimated completion is 2023-02-06.

What conditions does trial NCT05573685 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis, Fibromyalgia, Irritable Bowel Syndrome, Diabetic Neuropathy.

What interventions are being tested in trial NCT05573685?

The interventions under investigation include: DiNaMo Study App (DEVICE), Placebo App (DEVICE).

Who is sponsoring clinical trial NCT05573685?

This trial is sponsored by Click Therapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05573685 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.